The "Magnificent Seven" have lost some momentum in 2024, just as small-caps are starting to come on strong. Here's a closer look at five Russell 2000 stocks that are crushing the performance of their mega-cap...
Fate Therapeutics: Q4 Earnings Snapshot
Fate Therapeutics: Q3 Earnings Snapshot
Fate Therapeutics: Q2 Earnings Snapshot
The company's shares bounced back after a stock sale last week.
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 65.45% and 39.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics: Q1 Earnings Snapshot
Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.